α2C-adrenoceptor modulators: A patent review

Expert Opinion on Therapeutic Patents

Volumn 21, Issue 4, 2011, Pages 455-481

  Quaglia, Wilma ^a   Del Bello, Fabio ^a   Giannella, Mario ^a   Piergentili, Alessandro ^a   Pigini, Maria ^a  

^a UNIVERSITY OF CAMERINO   (Italy)

Author keywords

2C AR agonists; 2C AR antagonists; 2C AR modulators; 2C AR selectivity

Indexed keywords

1,3,4,5',6,6',7,12B OCTAHYDRO 1',3' DIMETHYL 2H SPIRO[BENZO[B]FURO[2,3 A]QUINOLIZINE 2,4' PYRIMIDINE] 2' ONE; 2 (1 METHYL 2 ISOINDOLINYLMETHYL) 2 IMIDAZOLINE; 2 (2,6 DIETHYLANILINO) 2 IMIDAZOLINE; 2 [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] 4,4 DIMETHYL 1,3(2H,4H) ISOQUINOLINEDIONE; ALPHA 2 ADRENERGIC RECEPTOR; ALPHA 2 ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA 2C ADRENERGIC RECEPTOR; ATIPAMEZOLE; BRIMONIDINE; BUSPIRONE; CIRAZOLINE; CLONIDINE; CLOZAPINE; DEXMEDETOMIDINE; FADOLMIDINE; IDAZOXAN; IMIDAZOLINE DERIVATIVE; JP 1302; MEDETOMIDINE; MIANSERIN; MIRTAZAPINE; MOXONIDINE; NOLOMIROLE; OXYMETAZOLINE; P 88 8991; QUETIAPINE; RAUWOLSCINE; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; UNINDEXED DRUG; YOHIMBINE; ZIPRASIDONE;

ADJUVANT THERAPY; ALCOHOL WITHDRAWAL; ALCOHOLISM; ALZHEIMER DISEASE; ANALGESIA; ANTINOCICEPTION; ANXIETY DISORDER; ATTENTION DEFICIT DISORDER; BEHAVIOR DISORDER; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHRONIC PAIN; COGNITIVE DEFECT; DEMENTIA; DEPRESSION; DIABETES MELLITUS; DRUG EFFECT; DRUG RECEPTOR BINDING; GENETIC VARIABILITY; GLAUCOMA; HEART ARRHYTHMIA; HEART FAILURE; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTENSION; HYPOTHERMIA; IMPOTENCE; LEARNING DISORDER; MOOD DISORDER; MYDRIASIS; NONHUMAN; NOSE CONGESTION; NUCLEOTIDE SEQUENCE; OBESITY; PAIN; PARKINSON DISEASE; PATENT; PERSONALITY DISORDER; POSITRON EMISSION TOMOGRAPHY; POSTTRAUMATIC STRESS DISORDER; RAYNAUD PHENOMENON; REVIEW; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCLERODERMA; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADRENERGIC ALPHA-2 RECEPTOR AGONISTS; ADRENERGIC ALPHA-2 RECEPTOR ANTAGONISTS; ANIMALS; HUMANS; MICE; PATENTS AS TOPIC; RECEPTORS, ADRENERGIC, ALPHA-2;

EID: 79952944848     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2011.565333     Document Type: Review

References (177)

1. Ahlquist RP. A study of the adrenotropic receptors. Am J Physiol 1948;153:586-600
2. Lands AM, Arnold A, McAuliff JP, et al. Differentiation of receptor systems activated by sympathomimetic amines. Nature 1967;214:597-8
3. Langer SZ. Presynaptic regulation of catecholamine release. Biochem Pharmacol 1974;23:1793-800
4. Berthelsen S, Pettinger WA. A functional basis for classification of alpha-adrenergic receptors. Life Sci 1977;21:595-606 (Pubitemid 8189368)
5. Michel MC, Kenny B, Schwinn DA. Classification of alpha 1-adrenoceptor subtypes. Naunyn Schmiedeberg's Arch Pharmacol 1995;352:1-10
6. MacDonald E, Kobilka BK, Scheinin M. Gene targeting-homing in on alpha2-adrenoceptor-subtype function. Trends Pharmacol Sci 1997;18:211-9
7. Hieble JP, Ruffolo RR Jr. Subclassification and nomenclature of alpha 1- and alpha 2-adrenoceptors. Prog Drug Res 1996;47:81-130
8. Hieble JP, Bondinell WE, Ruffolo RR Jr. alpha- and beta-Adrenoceptors: From the gene to the clinic. Part 1. Molecular biology and adrenoceptor subclassification. J Med Chem 1995;38:3415-44
9. Bylund DB, Eikenberg DC, Hieble JP, et al. International union of pharmacology nomenclature of adrenoceptors. Pharmacol Rev 1994;46:121-36
10. Bylund DB. Alpha- and beta-adrenergic receptors: Ahlquist's landmark hypothesis of a single mediator with two receptors. Am J Physiol Endocrinol Metab 2007;293:E1479-81 (Pubitemid 350255096)
11. Chalmers DT, Behan DP. The use of constitutively active GPCRs in drug discovery and functional genomics. Nat Rev Drug Discov 2002;1:599-608 (Pubitemid 37361523)
12. Gerhardt MA, Neubig RR. Multiple Gi protein subtypes regulate a single effector mechanism. Mol Pharmacol 1991;40:707-11
13. Eason MG, Kurose H, Holt BD, et al. Simultaneous coupling of alpha2-adrenergic receptors to two G-proteins with opposing effects. Subtype-selective coupling of alpha2C10, alpha2C4, and alpha2C2 adrenergic receptors to Gi and Gs. J Biol Chem 1992;267:15795-801
14. Eason MG, Jacinto MT, Liggett SB. Contribution to activation of alpha2-adrenergic receptor subtype coupling to Gs. Mol Pharmacol 1994;45:696-702 This study provides evidence for the a2-ARs to couple to Gi and Gs proteins eliciting opposing effects on the same effector enzyme. (Pubitemid 24139197)
15. Kobilka BK, Matsui H, Kobilka TS, et al. Cloning, sequencing and expression of the gene coding for the human platelet alpha2-adrenergic receptor. Science 1987;238:650-6 (Pubitemid 17158295)
16. Regan JW, Kobilka TS, Yang-Feng TL, et al. Cloning and expression of a human kidney cDNA for an alpha2-adrenergic receptor subtype. Proc Natl Acad Sci USA 1988;85:6301-5
17. Lomasney JW, Lorenz W, Allen LF, et al. Expansion of the alpha2-adrenergic receptor family: Cloning and characterization of a human alpha2-adrenergic receptor subtype, the gene for which is located on chromosome 2. Proc Natl Acad Sci USA 1990;87:5094-8
18. Weinshank RL, Zgombick JM, Macchi M, et al. Cloning, expression, and pharmacological characterization of a human alpha2B-adrenergic receptor. Mol Pharmacol 1990;38:681-8
19. Zeng D, Harrison JK, D'Angelo DD, et al. Molecular characterization of a rat alpha2B-adrenergic receptor. Proc Natl Acad Sci USA 1990;87:3102-6
20. Riess O, Thies U, Siedlaczck I, et al. Precise mapping of the brain alpha2-adrenergic receptor gene within chromosome 4p16. Genomics 1994;19:298-302 (Pubitemid 24059321)
21. Bousquet P. Imidazoline receptors: From basic concepts to recent developments. J Cardiovasc Pharmacol 1995;26:S1-6 (Pubitemid 26073316)
22. Reis DJ, Bousquet P, Parini A. The imidazoline receptor: Pharmacology, functions, ligands, and relevance to biology and medicine. Ann NY Acad Sci 1995;763:1-703
23. Gyires K, Zadori ZS, Torok T, Matyus P. alpha2-Adrenoreceptor subtypes-mediated physiological, pharmacological actions. Neurochem Int 2009;55:447-53 A report on physiological and pharmacological actions in which a2-ARs are involved.
24. Tan CM, Limbird LE. The alpha2 adrenergic receptors: lessons from knockouts. In the adrenergic receptors in the 21st century. Humana Press, Inc., NJ; 2006. p. 241-65
25. Kable JW, Murrin LC, Bylund DB. In vivo gene modification elucidates subtype-specific functions of alpha2-adrenergic receptors. J Pharmacol Exp Ther 2000;293:1-7 (Pubitemid 30180916)
26. MacMillan LB, Hein L, Smith MS, et al. Central hypotensive effects of the alpha2a-adrenergic receptor subtype. Science 1996;273:801-3 (Pubitemid 26271526)
27. Makaritsis KP, Handy DE, Johns C, et al. Role of the alpha2B-adrenergic receptor in the development of salt-induced hypertension. Hypertension 1999;33:14-7 (Pubitemid 29061835)
28. Philipp M, Brede M, Hein L. Physiological significance of alpha2-adrenergic receptor subtype diversity: one receptor is not enough. Am J Physiol Regul Integr Comp Physiol 2002;283:R287-95 (Pubitemid 34863874)
29. Gaspar R, Gal A, Galik M, et al. Different roles of alpha2-adrenoceptor subtypes in non-pregnant and late-pregnant uterine contractility in vitro in the rat. Neurochem Int 2007;51:311-8 (Pubitemid 47374324)
30. Guo TZ, Davies MF, Kingery WS, et al. Nitrous oxide produces antinociceptive response via alpha2B and/or alpha2C adrenoceptor subtypes in mice. Anesthesiology 1999;90:470-6 (Pubitemid 29071516)
31. Hein L, Altman JD, Kobilka BK. Two functionally distinct alpha2-adrenergic receptors regulate sympathetic neurotransmission. Nature 1999;402:181-4
32. Bucheler MM, Haldamek K, Hein L. Two alpha2-adrenergic receptor subtypes, alpha2A and alpha2C, inhibit transmitter release in the brain of gene-targeted mice. Neuroscience 2002;109:819-26 (Pubitemid 34260866)
33. Knaus AE, Muthig V, Schickinger S, et al. alpha2-Adrenoceptor subtypes - Unexpected functions for receptors and ligands derived from gene-targeted mouse models. Neurochem Int 2007;51:277-81 (Pubitemid 47374320)
34. Scheibner J, Trendelenburg AU, Hein L, Starke K. alpha2-adrenoceptors modulating neuronal serotonin release: A study in alpha2-adrenoceptor subtypedeficient mice. Br J Pharmacol 2001;132:925-33 (Pubitemid 32193650)
35. Chotani MA, Flavahan S, Mitra S, et al. Silent alpha2C-adrenergic receptors enable cold-induced vasoconstriction in cutaneous arteries. Am J Physiol Heart Circ Physiol 2000;278:H1075-83 (Pubitemid 30235482)
36. Chotani MA, Mitra S, Su BY, et al. Regulation of alpha(2)-adrenoceptors in human vascular smooth muscle cells. Am J Physiol Heart Circ Physiol 2004;286:H59-67 (Pubitemid 38049463)
37. Flavahan NA, Flavahan S, Mitra S, Chotani MA. The vasculopathy of Raynaud's phenomenon and scleroderma. Rheum Dis Clin North Am 2003;29:275-91 (Pubitemid 36765121)
38. Bjorklund M, Sirvio J, Sallinen J, et al. Alpha2C-adrenoceptor overexpression disrupts execution of spatial and non-spatial search patterns. Neuroscience 1999;88:1187-98 (Pubitemid 28546997)
39. Tanila H, Mustonen K, Sallinen M, Riekkinen P Jr. Role of alpha2C-adrenoceptor subtype in spatial working memory as revealed by mice with targeted disruption of the alpha2C-adrenoceptor gene. Eur J Neurosci 1999;11:599-603 (Pubitemid 29050461)
40. Rohrer DK, Kobilka BK. Insights from in vivo modification of adrenergic receptor gene expression. Annu Rev Pharmacol Toxicol 1998;38:351-73 (Pubitemid 28231499)
41. Sallinen J, Haapalinna A, Viitamaa T, et al. Adrenergic alpha2C-receptors modulate the acoustic startle reflex, prepulse inhibition, and aggression in mice. J Neurosci 1998;18:3035-42 (Pubitemid 28163233)
42. Sallinen J, Haapalinna A, Viitamaa T, et al. D-amphetamine and L-5- hydroxytryptophan-induced behaviours in mice with genetically-altered expression of the alpha2C-adrenergic receptor subtype. Neuroscience 1998;86:959-65 (Pubitemid 28298750)
43. Scheinin M, Sallinen J, Haapalinna A. Evaluation of the alpha2C-adrenoceptor as a neuropsychiatric drug target. Studies in transgenic mouse models. Life Sci 2001;68:2277-85
44. Fairbanks CA, Stone LS, Kitto KF, et al. alpha2C-Adrenergic receptors mediate spinal analgesia and adrenergic-opioid synergy. J Pharmacol Exp Ther 2002;300:282-90 (Pubitemid 34028538)
45. Liggett SB, Shah SD, Cryer PE. Human tissue adrenergic receptors are not predictive of responses to epinephrine in vivo. Amer J Physiol 1989;256:E600-9
46. Van Campen LC, Visser FC, Visser CA. Ejection fraction improvement by beta-blocker treatment in patients with heart failure: An analysis of studies published in the literature. J Cardiovasc Pharmacol 1998;32:S31-5 (Pubitemid 28415089)
47. Israel E, Drazen JM, Liggett SB, et al. The effect of polymorphisms of the beta2-adrenergic receptor on the response to regular use of albuterol in asthma. Amer J Respir Crit Care Med 2000;162:75-80 (Pubitemid 30469801)
48. Small KM, McGraw DW, Liggett SB. Pharmacology and physiology of human adrenergic receptor polymorphisms. Annu Rev Pharmacol Toxicol 2003;43:381-411 (Pubitemid 37372647)
49. Small KM, Wagoner LE, Levin AM, et al. Synergistic polymorphisms of beta1- and alpha2C-adrenergic receptors and the risk of congestive heart failure. N Engl J Med 2002;347:1135-42
50. Gerson MC, Wagoner LE, McGuire N, Liggett SB. Activity of the uptake-1 norepinephrine transporter as measured by I-123 MIBG in heart failure patients with a loss-of-function polymorphism of the presynaptic alpha2C-adrenergic receptor. J Nucl Cardiol 2003;10:583-9 (Pubitemid 38035392)
51. Brede M, Wiesmann F, Jahns R, et al. Feedback inhibition of catecholamine release by two different alpha2-adrenoceptor subtypes prevents progression of heart failure. Circulation 2002;106:2491-6 (Pubitemid 35278807)
52. Small KM, Forbes SL, Rahman FF, et al. A four amino acid deletion polymorphism in the third intracellular loop of the human alpha2C-adrenergic receptor confers impaired coupling to multiple effectors. J Biol Chem 2000;275:23059-64 (Pubitemid 30646196)
53. University of Cincinnati. Methods of cardiovascular disease assessment in an individual. WO023101; 2004
54. University of Cincinnati. Alpha-2 adrenergic receptor polymorphisms. WO079561; 2001
55. University of Cincinnati. Alpha-2 adrenergic receptor polymorphisms. US0113725; 2003
56. University of Cincinnati. Alpha-2 adrenergic receptor polymorphisms. US7572603; 2009
57. University of Cincinnati. Polymorphisms and haplotypes of the alpha 2C adrenergic receptor gene. WO04939; 2006 A patent claiming the use of a2C-AR gene polymorphisms in methods useful for diagnosis, prognosis and treatment of pathological conditions due to these variants.
58. Perlegen Sciences, Inc. Use of alpha-2 adrenergic receptor agonists. WO076655; 2006
59. Kamibayashi T, Maze M. Clinical uses of alpha2-adrenergic agonists. Anesthesiology 2000;93:1345-9
60. Bekker A, Jorden VSB. Alpha-2 agonists in neuroanestesia. Semin Anesth Perio M 2004;23:181-91
61. Calasans-Maia JA, Zapata-Sudo G, Sudo RT. Dexmedetomidine prolongs spinal anestesia induced by levobupivacaine 0.5% in guinea-pigs. J Pharm Pharmacol 2005;57:1415-20 (Pubitemid 350066983)
62. Kanazi GE, Aouad MT, Jabbour-Khoury SI, et al. Effect of low-dose dexmedetomidine or clonidine on the characteristics of bupivacaine spinal block. Acta Anaesthesiol Scand 2006;50:222-7 (Pubitemid 43340856)
63. Deutsch E, Tobias JD. Hemodynamic and respiratory changes following dexmedetomidine administration during general anesthesia: Sevoflurane vs desflurane. Pediatr Anesth 2007;17:438-44 (Pubitemid 46633389)
64. Schmidt AP, Valinetti EA, Bertacchi MF, et al. Effects of preanesthetic administration of midazolam, clonidine, or dexmedetomidine on postoperative pain and anxiety in children. Paediatr Anaesth 2007;17:667-74 (Pubitemid 46911071)
65. Shukry M, Kennedy K. Dexmedetomidine as a total intravenous anesthetic in infants. Pediatr Anesth 2007;17:581-3 (Pubitemid 46718185)
66. Laudenbach V, Mantz J, Lagercrantz H, et al. Effects of alpha2-adrenoceptor agonists on perinatal excitotoxic brain injury: Comparison of clonidine and dexmedetomidine. Anesthesiology 2002;96:134-41 (Pubitemid 34032493)
67. Paris A, Mantz J, Tonner PH, et al. The effects of dexmedetomidine on perinatal excitotoxic brain injury are mediated by the alpha2A-adrenoceptor subtype. Anesth Analg 2006;102:456-61 (Pubitemid 43152595)
68. Pertovaara A. Antinociceptive properties of fadolmidine (MPV-2426), a novel alpha2-adrenoceptor agonist. CNS Drug Rev 2004;10:117-26 (Pubitemid 38879106)
69. Onttonen T, Pertovaara A. The mechanical antihyperalgesic effect of intrathecally administered MPV-2426, a novel alpha2-adrenoceptor agonist, in a rat model of postoperative pain. Anesthesiology 2000;92:1740-5 (Pubitemid 30412495)
70. Xu M, Kontinen VK, Kalso E. Effects of radolmidine, a novel alpha2-adrenergic agonist compared with dexmedetomidine in different pain models in the rat. Anesthesiology 2000;93:473-81 (Pubitemid 30620322)
71. Ansah OB, Pertovaara A. Peripheral suppression of arthritic pain by intraarticular fadolmidine, an alpha 2-adrenoceptor agonist, in the rat. Anesth Analg 2007;105:245-50 (Pubitemid 46975872)
72. Niemi R, Huuskonen J, Laine K, Jarvinen T. Synthesis, hydrolysis, and intraocular pressure lowering effects of fadolmidine prodrugs. Int J Pharm 2005;295:121-7 (Pubitemid 40558795)
73. Stone LS, MacMillan LB, Kitto KF, et al. The alpha2a adrenergic receptor subtype mediates spinal analgesia evoked by alpha2 agonists and is necessary for spinal adrenergic-opioid synergy. J Neurosci 1997;17:7157-65 (Pubitemid 27427893)
74. Messier TL, Dorman CM, Brauner-Osborne H, et al. High throughput assays of cloned adrenergic, muscarinic, neurokinin, and neurotrophin receptors in living mammalian cells. Pharmacol Toxicol 1995;76:308-11
75. Pihlavisto M, Scheinin M. Functional assessment of recombinant human alpha2-adrenoceptor subtypes with cytosensor microphysiometry. Eur J Pharmacol 1999;385:247-53
76. Sullivan E, Tucker EM, Dale IL. Measurement of [Ca2+]using the fluorometric imaging plate reader (FLIPR). Methods Mol Biol 1999;114:125-33
77. Umland SP, Wan Y, Shah H, et al. Receptor reserve analysis of the human alpha2C-adrenoreceptor using [35S] GTPgammaS and cAMP functional assays. Eur J Pharmacol 2001;411:211-21 (Pubitemid 32119591)
78. Allergan Sales, Inc. Compounds as selective agonists as alpha 2B or 2B/2C adrenergic receptors. WO0586; 2001
79. Allergan Sales, Inc. Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors. WO076950; 2002
80. Allergan Sales, Inc. Compounds and method of treatment having agonist-like activity selective at alpha 2B or 2B/2C adrenergic receptors. US023098; 2003
81. Allergan Sales, Inc. 7-[(1H-imidazol-4-yl) methyl]-5,6,7,8- tetrahydroquinoline. US179182; 2007
82. Allergan Sales, Inc. (2-Hydroxy)ethylthioureas useful as modulators of alpha2B adrenergic receptors. WO068384; 2002
83. Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity. WO078702; 2001
84. Allergan Sales, Inc. Methods and compositions for modulating alpha adrenergic receptor activity. US058839; 2002
85. Dirig DM, Salami A, Rathbun ML, et al. Characterization of variables defining hindpaw withdrawal latency evoked by radiant thermal stimuli. J Neurosci Methods 1997;76:183-91 (Pubitemid 27428253)
86. Kim SH, Chung JM. An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992;50:355-63
87. Allergan Sales, Inc. Therapeutic fluoroethylcyano guanidines. US0255230; 2008
88. Allergan Sales, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents. US0255239; 2008
89. Allergan Sales, Inc. Aryl fluoroethyl ureas acting as alpha 2 adrenergic agents. US0194650; 2008
90. Allergan Sales, Inc. Therapeutic fluoroethyl ureas. US0270498; 2007
91. Allergan Sales, Inc. Substituted fluoroethyl ureas as alpha 2 adrenergic agents. WO09278; 2009
92. Allergan Sales, Inc. 4-Substituted imidazole-2-thiones and imidazol-2-ones as agonists of the alpha-2B and alpha-2C adrenergic receptors. WO099795; 2003
93. Allergan Sales, Inc. 4-(Substituted cycloalkylmethyl)imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl)imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds. US0220402; 2004
94. Allergan Sales, Inc. 2-[(2-Thioxo-2, 3-dihydro-1H-imidazol-4-yl)methyl]- 3, 4-dihydro-naphthalen-1(2H)-one. US0148872; 2006
95. Allergan Sales, Inc. Methods and compositions for the treatment of diabetes. US20293359; 2006
96. Allergan Sales, Inc. Unsubstituted and substituted 4-benzyl-1,3- dihydroimidazole- 2-thiones acting as specific or selective alpha2 adrenergic agonists and methods for using the same. US069142; 2006
97. Allergan Sales, Inc. 4-(Phenylmethyl and substituted phenylmethyl)- imidazole-2-thiones acting as specific alpha2 adrenergic agonists. WO036480; 2006
98. Allergan Sales, Inc. 4-(Condensed cyclicmethyl)-imidazole-2-thiones acting as alpha2 adrenergic agonists. US069144; 2006
99. Schering Corp. Alpha2C adrenoreceptor agonists. WO024949; 2007
100. Allergan Sales, Inc. Alpha-2 adrenergic agonists. US04789; 2007
101. Allergan Sales, Inc. Alpha-2 adrenergic agonists for the treatment of pain. WO05177; 2007
102. Allergan Sales, Inc. 4-(Substituted cycloalkylmethyl)imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4-(substituted cycloalkylmethyl)imidazol-2-ones and 4-(substituted cycloalkenylmethyl) imidazol-2-ones and related compounds. US072926; 2007
103. Allergan Sales, Inc. Methods and compositions for the treatment of hyperlipidemia. WO014299; 2008
104. Allergan Sales, Inc. Method of treating sensorimotor disorders with alpha-2 adrenergic receptor agonists. WO052073; 2009
105. Allergan Sales, Inc. Alpha 2B or 2B/2C adrenoceptor agonists for the treatment of neurodegeneration. WO032913; 2004
106. Allergan Sales, Inc. Therapeutic [(phenyl) imidazolyl]methylquinolinyl compounds. WO147788; 2008
107. Allergan Sales, Inc. Quinolynylmethylimidazoles as therapeutic agents. WO140138; 2009
108. Allergan Sales, Inc. Substituted-[aryl (imidazole)methyl]phenyl compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors. WO091735; 2009
109. Schering Corp. Imidazole derivatives as functionally selective alpha2C adrenoreceptor agonists. WO024944; 2007
110. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. WO100456; 2008
111. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. WO100457; 2008
112. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. US0197562; 2010
113. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. US027100; 2008
114. Schering Corp. Alpha2C adrenoreceptor agonists. US039439; 2008
115. Schering Corp. 3,4-Dihydro-1, 4-benzoxazine, 3,4-dihydro- 1,4-benzothiazine and 1,2,3,4-tetrahydroquinoxaline derivatives as alpha2C adrenoreceptor agonists. WO100463; 2008
116. Schering Corp. Derivatives and analogs of chroman as functionally selective alpha2C adrenoreceptor agonists. WO100459; 2008
117. Merck. Derivatives and analogs of chroman as functionally selective alpha2C adrenoreceptor agonists. US0168195; 2010
118. F. Hoffmann-La Roche AG. Substituted 4-imidazoles. WO058867; 2008
119. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. WO105504; 2009
120. Schering Corp. Functionally selective alpha2C adrenoreceptor agonists. WO100480; 2008 A patent disclosing some isotopically-labeled compounds developed for medical imaging PET and SPECT.
121. Allergan Sales, Inc. Pharmaceutical compositions comprising (3-(1-(1Himidazol- 4-yl)ethyl)-2-methylphenyl) methanol. WO093930; 2010
122. Stoilov I, Watt DS, Goodman JP, Pyrek JST. Synthesis of detomidine and medetomidine metabolites: 1,2,3-trisubstituted arenes with 4'(5')- imidazolylmethyl groups. J Heterocyclic Chem 1993;30:1645-51
123. Allergan Sales, Inc. Pyridine compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors. WO091209; 2010
124. Allergan Sales, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof. WO140204; 2009
125. Allergan Sales, Inc. N-(1-phenyl-2- arylethyl)-4,5-dihydro-2H-pyrrol-5- amine compounds as subtype selective modulators of alpha2B or alpha2B and alpha2C adrenoceptors. US145061; 2010
126. Allergan Sales, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof. WO091759; 2009
127. Allergan Sales, Inc. Oxazolidine and thiazolidine selective subtype alpha 2 adrenergic agents and methods for use thereof. WO091760; 2009
128. Allergan Sales, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof. US0239918; 2009
129. Allergan Sales, Inc. Alpha2B and alpha2C agonists. US0275627; 2009 A patent claiming a2C-agonists highly selective over the other a2-AR subtypes.
130. Allergan Sales, Inc. Selective subtype alpha 2 adrenergic agents and methods for use thereof. WO120648; 2009
131. Schering Corp. Alpha2C adrenoreceptor agonists. WO020578; 2009
132. Schering Corp. Fuctionally selective azanitrile alpha2C adrenoreceptor agonists. WO033495; 2010
133. Allergan Sales, Inc. Substituted-aryl-2- phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors. US0176843; 2009
134. Allergan Sales, Inc. Substituted-aryl-2- phenylethyl-1H-imidazole compounds as subtype selective modulators of alpha 2B and/or alpha 2C adrenergic receptors. WO089132; 2009
135. Schering Corp. Cyclopropylchromene derivatives as modulators of the alpha-2C receptor. WO017120; 2010 A patent presenting a typical case where small changes of the chemical structure induce agonism/antagonism modulation.
136. Schering Corp. Biaryl spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators. WO042473; 2010
137. Schering Corp. Spiroaminooxazoline analogues as alpha2C adrenergic receptor modulators. WO042475; 2010
138. Gentili F, Pigini M, Piergentili A, Giannella M. Agonists and antagonists targeting the different alpha2-adrenoceptor subtypes. Curr Top Med Chem 2007;7:163-86 (Pubitemid 46062388)
139. Maura G, Bonanno G, Raiteri M. Presynaptic alpha2-adrenoceptors mediating inhibition of noradrenaline and 5-hydroxytryptamine release in rat cerebral cortex: Further characterization as different alpha2-adrenoceptor subtypes. Naunyn Schmiedeberg's Arch Pharmacol 1992;345:410-16
140. Tellez S, Colpaert F, Marien M. Acetylcholine release in the rat prefrontal cortex in vivo: modulation by alpha2-adrenoceptor agonists and antagonists. J Neurochem 1997;68:778-85 (Pubitemid 27044743)
141. Janssen Pharmaceutica N.V. Benzothieno [3,2-c]pyridines as alpha2 antagonists. WO020422; 2000
142. Orion Corp. Use of an alpha2-adrenoreceptor antagonist for CNS-related diseases. WO082825; 2003
143. Orion Corp. Derivatives of quinoline as alpha-2 antagonists. WO064645; 2001 A patent claiming a2C-antagonists highly selective over the other a2-AR subtypes.
144. Sallinen J, Hoglund I, Engstrom M, et al. Pharmacological characterization and CNS effects of a novel highly selective alpha2C-adrenoceptor antagonist JP-1302. Brit J Pharmacol 2007;150:391-402 (Pubitemid 46280650)
145. Massachusetts Menthal Health Inst. Treating alcohol and/or substance abuse by antagonizing alpha2 adrenergic receptors with weak dopamine blocking. WO034996; 2004
146. Fish & Richardson PC. Combinations of dopamine D2 receptor blockade with norepinephrine reuptake inhibition and with norepinephrine alpha 2 receptor blockade. US0188464; 2008 Combination of D2 dopaminergic receptor antagonist, NE reuptake inhibition and a2C-antagonist as a method of treating or preventing substance abuse/dependence.
147. Janssen Pharmaceutica N.V. Triazolone, tetrazolone and imidazolone derivatives for use as alpha-2C adrenoreceptor antagonists. WO067139; 2006
148. Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine. WO122173; 2007
149. Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives for use as a medicine. WO135131; 2007
150. Janssen Pharmaceutica N.V. Substituted pyrazinone derivatives as alpha 2C-adrenoreceptor antagonists. WO071639; 2007
151. Oy Juvantia Pharma Ltd. Antagonists for alpha-2 adrenoceptors. WO067513; 2004
152. Kyowa Hakko Kogyo Co., Ltd. Receptor antagonist. WO028732; 2003
153. Janssen Pharmaceutica N.V. Substituted amino isoxazoline derivatives and their use as anti-depressants. WO082878; 2003
154. Orion Corp. Polycyclic compounds as potent alpha2-adrenoceptor antagonists. WO082866; 2003
155. Finnegarn, Henderson, Farabow, Garrett & Dunner LLP. Polycyclic compounds as potent alpha2-adrenoceptor antagonists. US094740; 2006
156. Finnegarn, Henderson, Farabow, Garrett & Dunner LLP. Polycyclic compounds as potent alpha2-adrenoceptor antagonists. US0293527; 2007
157. Orion Corp. Polycyclic compounds as potent alpha2-adrenoceptor antagonists. US7592350; 2009
158. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors-focus on newer generation compounds. Life Sc 2000;68:29-39
159. Mutlib AE, Strupczewski JT, Chesson SM. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos 1995;23:951-64
160. Novartis AG. Optical isomers of an iloperidone metabolite. WO020707; 2003
161. Taisho Pharmaceutical Co., Ltd. Cyclic amine compound. WO100355; 2005
162. Kyowa Hakko Kogyo Co., Ltd. Preparation of benzofuran derivatives as adrenaline alpha2c receptor antagonists. JP139106; 2005
163. Schering Corp. Benzodioxan analogues as alpha2C adrenergic receptor modulators. WO042477; 2010
164. Dabire H. Idazoxan: A novel pharmacological tool for the study of alpha2-adrenoceptors. J Pharmacol 1986;17:113-18 (Pubitemid 16097460)
165. O'Rourke MF, Blaxall HS, Iversen LJ, Bylund DB. Characterization of [3H] RX821002 binding to alpha2-adrenergic receptor subtypes. J Pharmacol Exp Ther 1994;268:1362-7 (Pubitemid 24100354)
166. Gentili F, Cardinaletti C, Vesprini C, et al. alpha2-Adrenoreceptors profile modulation. 4. From antagonist to agonist behaviour. J Med Chem 2008;51:4289-99 (Pubitemid 352032453)
167. Orion Corp. Aryl piperazines and their use as alpha2C antagonists. WO058060; 2010 A patent disclosing some a2C-antagonists incorporating different radionuclides for PET studies.
168. Orion Corp. 2,3-Dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases. WO013390; 2009
169. Finnegarn, Henderson, Farabow, Garrett & Dunner LLP. 2,3-Dihydrobenzo[1,4] dioxin-2-ylmethyl derivatives as alpha2C antagonists for use in the treatment of peripheric and central nervous system diseases. US0216836; 2010
170. Zheng W, Lei L, Lalchandani SG, et al. Yohimbine dimers exhibiting binding selectivities for human alpha2a- versus alpha2b-adrenergic receptors. Bioorg Med Chem Lett 2000;10:627-30 (Pubitemid 30186665)
171. Lalchandani SG, Lei L, Zheng W, et al. Yohimbine dimers exhibiting selectivity for the human alpha2C-adrenoreceptor subtype. J Pharmacol Exper Ther 2002;303:979-84 (Pubitemid 35424379)
172. The University of Tennessee Research Foundation and the University of Mississippi. Yohimbine derivatives and use thereof. US7470703; 2008
173. The Ohio State University Research Foundation. Methods and compositions for treating Raynaud's phenomenon and scleroderma. US6444681; 2002
174. The Ohio State University Research Foundation. Methods and compositions for treating Raynaud's phenomenon and scleroderma. WO076502; 2000
175. Harker CT, Vanhoutte PM. Cooling the central ear artery of the rabbit: myogenic and adrenergic responses. J Pharmacol Exp Ther 1988;245:89-93
176. Del Bello F, Mattioli L, Ghelfi F, et al. Fruitful adrenergic alpha2C-agonism/ alpha2A-antagonism combination to prevent and contrast morphine tolerance and dependence. J Med Chem 2010;53:7825-35 Results of this study suggest the therapeutic potential of novel ligands as adjuvant agents in the management of pain with morphine.
177. Vacher B, Funes P, Chopin P, et al. Rigid analogues of the alpha2-adrenergic blocker atipamezole: Small changes, big consequences. J Med Chem 2010;53:6986-95